{"name":"Laboratorio Elea Phoenix S.A.","slug":"laboratorio-elea-phoenix-s-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Short regimen of benznidazole","genericName":"Short regimen of benznidazole","slug":"short-regimen-of-benznidazole","indication":"Chagas disease (Trypanosoma cruzi infection) — acute and chronic phases","status":"phase_3"},{"name":"Short treatment with benznidazole","genericName":"Short treatment with benznidazole","slug":"short-treatment-with-benznidazole","indication":"Chagas disease (Trypanosoma cruzi infection), chronic phase","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Standard treatment with benznidazole","genericName":"Standard treatment with benznidazole","slug":"standard-treatment-with-benznidazole","indication":"Chagas disease","status":"phase_3"},{"name":"Efavirenz, tenofovir disoproxil fumarate and emtricitabine","genericName":"Efavirenz, tenofovir disoproxil fumarate and emtricitabine","slug":"efavirenz-tenofovir-disoproxil-fumarate-and-emtricitabine","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Bevacizumab (Lumiere®)","genericName":"Bevacizumab (Lumiere®)","slug":"bevacizumab-lumiere","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"Pembrolizumab biosimilar","genericName":"Pembrolizumab biosimilar","slug":"pembrolizumab-biosimilar","indication":"Metastatic melanoma","status":"phase_3"}]}],"pipeline":[{"name":"Short regimen of benznidazole","genericName":"Short regimen of benznidazole","slug":"short-regimen-of-benznidazole","phase":"phase_3","mechanism":"Benznidazole is a nitroimidazole antiparasitic that generates reactive metabolites to damage the DNA and cellular structures of Trypanosoma cruzi parasites.","indications":["Chagas disease (Trypanosoma cruzi infection) — acute and chronic phases"],"catalyst":""},{"name":"Standard treatment with benznidazole","genericName":"Standard treatment with benznidazole","slug":"standard-treatment-with-benznidazole","phase":"phase_3","mechanism":"Benznidazole is an antiparasitic drug that works by inhibiting the growth of the parasite Trypanosoma cruzi.","indications":["Chagas disease"],"catalyst":""},{"name":"Bevacizumab (Lumiere®)","genericName":"Bevacizumab (Lumiere®)","slug":"bevacizumab-lumiere","phase":"phase_3","mechanism":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.","indications":["Metastatic colorectal cancer","Non-small cell lung cancer","Metastatic breast cancer","Renal cell carcinoma","Glioblastoma"],"catalyst":""},{"name":"Efavirenz, tenofovir disoproxil fumarate and emtricitabine","genericName":"Efavirenz, tenofovir disoproxil fumarate and emtricitabine","slug":"efavirenz-tenofovir-disoproxil-fumarate-and-emtricitabine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Pembrolizumab biosimilar","genericName":"Pembrolizumab biosimilar","slug":"pembrolizumab-biosimilar","phase":"phase_3","mechanism":"This biosimilar blocks PD-1 on immune cells to restore anti-tumor immunity by preventing tumor cells from suppressing T-cell responses.","indications":["Metastatic melanoma","Non-small cell lung cancer (NSCLC)","Head and neck squamous cell carcinoma","Hodgkin lymphoma","Urothelial carcinoma"],"catalyst":""},{"name":"Short treatment with benznidazole","genericName":"Short treatment with benznidazole","slug":"short-treatment-with-benznidazole","phase":"phase_3","mechanism":"Benznidazole is a nitroimidazole antiparasitic that generates reactive metabolites to damage the DNA and proteins of Trypanosoma cruzi, the parasite causing Chagas disease.","indications":["Chagas disease (Trypanosoma cruzi infection), chronic phase"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxNd19MU1pGNFQ3STFRb2k0cjB1UXRxY250cHZFY1dYeGlRMC01bFMwUURNUmFoU2dTSjdaV3pXeVFRVUpBNjJRbGtnYzY4ZjF4elhGTFgtV1JmTlhyMzVKc29SeW5iVW5UQU9BLVUzaEQ5bHNNSkx5Zm1BTC1Eb1FXaGRrY3JfcUxEVGdUOE1CWDEzR21jbUhHQ1Y1ZUpCRTRvd3Y5QXdkVFdVQlQtWXZhcXU1RUJfOHB2NDVwQUtsMGtEQkw0SEdwWmhXTVV1VWloMkZHZ0lNemRnSXNoWUlocGl6V244VUhrZWp2U0NiU0xxWElYZkJybjRKOW5TaHJZWTVFVmJFYnZaaF9PLS14SXludm9MQW1WWUlBLVVQRmptakNjczZxcTlhTVRkWTFEMmVuUzlPZEJPOVRYb2hoN1Q1WU9tdlE?oc=5","date":"2026-03-30","type":"pipeline","source":"GlobeNewswire","summary":"Neuroblastoma Market Analysis Report 2026-2030 | Rising - GlobeNewswire","headline":"Neuroblastoma Market Analysis Report 2026-2030 | Rising","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxQd2pnNl93NVIwN3dSMmpYSGNmQVMxZ2Z2SFRGSi1JN1A0aTFuWFRFRDVsN1VmT2Z1UW1WT0QzUXYwSXptQ3lIRTZ3ZDRJc3NVdnI5ZVFZQ3BSSlRHLWU2Z2RzY1Fwa3RjcGhSdERtMU1IanNqajJVRnJnd0dwMHRaRTU5MG9UR2lPeHJUODd2Nk95OWQ0Smx3bGdIc1ZCMEUtUkxxakVyY2NvU1BfZ3RWQ2xfNFpBcVRfQUVHM1Nvd2dIMWR0cTdVd0p0RHBuN3pzNkFHd3Rrc1ctTWlBVFRxcDFxLUJadUExRzkxNHJjQnZzUl9WSGZzMnBkZXFWQ2FrN0I0eHJNNnM?oc=5","date":"2025-08-14","type":"pipeline","source":"PR Newswire","summary":"Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight - PR Newswire","headline":"Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveIns","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-09-28","type":"pipeline","source":"PR Newswire","summary":"Neuroblastoma Market to Grow at a Substantial Growth Rate During the Forecast Period (2023-2032), Examines DelveInsight | Key Companies to Watch - Y-mAbs, Exelixis, Clarity, Eli Lilly, Innervate Radio","headline":"Neuroblastoma Market to Grow at a Substantial Growth Rate During the Forecast Period (2023-2032), Examines DelveInsight ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPdGJMQ1JvTTVmZEpkeWtWdW9uRmNSWkNWaklfMl9DZUE3TUE0NHhIbVNyOFRTSmQwMUtObnF4c1JReklRbUxhOUxOVDZCaG9BN0tOU3lScURSQ3huMzAtSEdyV2IzTEdIRDdlZ0FfM3hGNlRvUHRfZVZGalZPeEowdlFYd3kwaGc?oc=5","date":"2022-04-10","type":"regulatory","source":"Generics and Biosimilars Initiative","summary":"Biosimilars approved in Argentina - Generics and Biosimilars Initiative","headline":"Biosimilars approved in Argentina","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOWVZHcEZjWlM3cV9hUjVJbmNjVDdFdy00Y2NrR1VvX1RVZ1JQMTEzc09jWElxLWNEU0hxY0hPMVJONW03d0R2SmVRa2FoZllPYjRBcWRiOXE5WFl6bEZndUZFTjVnZ25oR3VvUEJxMUlUS00xdndYN3JNWGtFRHIyd1oycHZQc2hDM2hoN21GbGFCWmllY0p6ZnBmbFpWemJXN04zeW1nMFluejJGQ1RXZHdsV3RzR2dJUXNJTGJvYWxSLUdTNWJxZg?oc=5","date":"2010-06-09","type":"pipeline","source":"GSK","summary":"GSK drives Latin America growth strategy with acquisition of Laboratorios Phoenix - GSK","headline":"GSK drives Latin America growth strategy with acquisition of Laboratorios Phoenix","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":5,"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}